[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581319":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":55,"collaborators":24,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":24,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":24,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lidocaine group","EXPERIMENTAL","Patients will receive lidocaine (1.5 mg\u002Fkg loading then 1mg\u002Fkg\u002Fh infusion) just after induction of anesthesia induction and continued until the end of the operation.",[13],"Drug: Lidocaine",{"label":15,"type":10,"description":16,"interventionNames":17},"Dexmedetomidine group","Patients will receive 1 μg\u002Fkg dexmedetomidine infusion over 10 min as a loading dose then 0.4-0.7 μg\u002Fkg\u002Fh just after induction of anesthesia induction and continued until the end of the operation.",[18],"Drug: Dexmedetomidine",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","Lidocaine",[9],null,{"type":21,"name":26,"description":16,"armGroupLabels":27,"otherNames":24},"Dexmedetomidine",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Ahmed M Eldemerdash, MD","CONTACT","00201114959206","ahmedmonier@med.asu.edu.eg",[35],{"facility":5,"status":36,"city":37,"state":24,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Cairo","11591","Egypt","EG",{"type":42,"coordinates":43},"Point",[44,45],31.24967,30.06263,{"lat":45,"lon":44},[48,50,53],{"name":49,"role":31,"phone":32,"phoneExt":24,"email":33},"Ahmed M Eldemerdash",{"name":51,"role":52,"phone":24,"phoneExt":24,"email":24},"Sarah A Afifi, MD","PRINCIPAL_INVESTIGATOR",{"name":54,"role":52,"phone":24,"phoneExt":24,"email":24},"Sondos Afifi, MD",{"type":52,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Ahmed Monier Ahmed Youssef Eldemerdash","Lecturer of Anesthesia, Intensive care, and pain management Faculty of Medicine Ain Shams University","100581319","lidocaine-and-dexmedetomidine-infusions-for-intraoperative-bleeding-in-functional-endoscopic-sinus-surgery-100581319",false,"NCT06848764","Lidocaine and Dexmedetomidine Infusions for Intraoperative Bleeding in Functional Endoscopic Sinus Surgery","A Randomized Double-Blind Trial Comparing Lidocaine and Dexmedetomidine Infusions for Intraoperative Bleeding in Patients Undergoing Functional Endoscopic Sinus Surgery","Inclusion Criteria:\n\n* Age from 18 to 65 years old.\n* American Society of Anesthesiologists (ASA) physical status I - II.\n* Scheduled for elective functional endoscopic sinus surgery.\n\nExclusion Criteria:\n\n* Diabetes mellitus.\n* Coagulation disorders.\n* Kidney and liver dysfunction.\n* Cerebrovascular disease.\n* Cardiovascular problems.\n* High blood pressure.\n* Asthma.\n* Chronic obstructive pulmonary disease (COPD).\n* End organ damage.\n* Psychosis.\n* Taking antipsychotic drugs.\n* Allergy to study drugs.\n* Substance abuse.\n* Taking beta blockers.\n* Heart rate of \\\u003C 55 beat\u002Fminute.","ALL","18 Years","65 Years",{"count":69,"type":70},40,"ESTIMATED","INTERVENTIONAL",[73],"NA","This work aims to compare lidocaine and dexmedetomidine infusions for intraoperative bleeding in patients undergoing functional endoscopic sinus surgery.",[22,26,76,77,78],"Infusion","Intraoperative Bleeding","Functional Endoscopic Sinus Surgery","2025-03-01",{"date":81,"type":82},"2025-03-05","ACTUAL",{"date":79,"type":82},{"date":85,"type":70},"2025-09-01",{"name":5,"class":6},1]